{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:41:20Z","timestamp":1790768480023,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T00:00:00Z","timestamp":1546646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K12CA132783-01A1"],"award-info":[{"award-number":["1K12CA132783-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10637-018-00717-9","type":"journal-article","created":{"date-parts":[[2019,1,5]],"date-time":"2019-01-05T08:36:24Z","timestamp":1546677384000},"page":"948-960","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib"],"prefix":"10.1007","volume":"37","author":[{"given":"Titto","family":"Augustine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhashree","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,5]]},"reference":[{"issue":"11","key":"717_CR1","doi-asserted-by":"publisher","first-page":"e50701","DOI":"10.1371\/journal.pone.0050701","volume":"7","author":"YL Lin","year":"2012","unstructured":"Lin YL, Liau JY, Yu SC, Ou DL, Lin LI, Tseng LH, Chang YL, Yeh KH, Cheng AL (2012) KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells. PLoS One 7(11):e50701. https:\/\/doi.org\/10.1371\/journal.pone.0050701","journal-title":"PLoS One"},{"issue":"6","key":"717_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/1758834015603313","volume":"7","author":"GJ Peters","year":"2015","unstructured":"Peters GJ (2015) Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies. Ther Adv Med Oncol 7(6):340\u2013356. https:\/\/doi.org\/10.1177\/1758834015603313","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"717_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/DCR.0b013e3182023bb0","volume":"54","author":"C Platell","year":"2011","unstructured":"Platell C, Ng S, O'Bichere A, Tebbutt N (2011) Changing management and survival in patients with stage IV colorectal cancer. Dis Colon Rectum 54(2):214\u2013219. https:\/\/doi.org\/10.1007\/DCR.0b013e3182023bb0","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"717_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9\u201323. https:\/\/doi.org\/10.1016\/j.ctrv.2006.09.006","journal-title":"Cancer Treat Rev"},{"issue":"50","key":"717_CR5","doi-asserted-by":"publisher","first-page":"87044","DOI":"10.18632\/oncotarget.19667","volume":"8","author":"A Osoegawa","year":"2017","unstructured":"Osoegawa A, Gills JJ, Kawabata S, Dennis PA (2017) Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib. Oncotarget 8(50):87044\u201387053. https:\/\/doi.org\/10.18632\/oncotarget.19667","journal-title":"Oncotarget"},{"issue":"3","key":"717_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","volume":"14","author":"H Wei","year":"2016","unstructured":"Wei H, Yu X (2016) Functions of PARylation in DNA damage repair pathways. Genomics Proteomics Bioinformatics 14(3):131\u2013139. https:\/\/doi.org\/10.1016\/j.gpb.2016.05.001","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"18","key":"717_CR7","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1517\/14656566.2015.1100168","volume":"16","author":"O Dizdar","year":"2015","unstructured":"Dizdar O, Arslan C, Altundag K (2015) Advances in PARP inhibitors for the treatment of breast cancer. Expert Opin Pharmacother 16(18):2751\u20132758. https:\/\/doi.org\/10.1517\/14656566.2015.1100168","journal-title":"Expert Opin Pharmacother"},{"issue":"Pt 1","key":"717_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1042\/BJ20040776","volume":"386","author":"JA Munoz-Gamez","year":"2005","unstructured":"Munoz-Gamez JA, Martin-Oliva D, Aguilar-Quesada R, Canuelo A, Nunez MI, Valenzuela MT, Ruiz de Almodovar JM, De Murcia G, Oliver FJ (2005) PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. Biochem J 386(Pt 1):119\u2013125. https:\/\/doi.org\/10.1042\/BJ20040776","journal-title":"Biochem J"},{"issue":"2","key":"717_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.23736\/S0026-4784.17.04152-1","volume":"70","author":"C Walsh","year":"2018","unstructured":"Walsh C (2018) Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Ginecol 70(2):150\u2013170. https:\/\/doi.org\/10.23736\/S0026-4784.17.04152-1","journal-title":"Minerva Ginecol"},{"issue":"3","key":"717_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3(3):e00149. https:\/\/doi.org\/10.1002\/prp2.149","journal-title":"Pharmacol Res Perspect"},{"issue":"3","key":"717_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1124\/jpet.113.210146","volume":"349","author":"J Murai","year":"2014","unstructured":"Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y (2014) Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349(3):408\u2013416. https:\/\/doi.org\/10.1124\/jpet.113.210146","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"717_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/bjc.2014.561","volume":"112","author":"TA Augustine","year":"2015","unstructured":"Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S (2015) Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer 112(2):313\u2013318. https:\/\/doi.org\/10.1038\/bjc.2014.561","journal-title":"Br J Cancer"},{"key":"717_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s12029-017-9954-5","volume":"49","author":"JS Gandhi","year":"2017","unstructured":"Gandhi JS, Goswami M, Sharma A, Tanwar P, Gupta G, Gupta N, Pasricha S, Mehta A, Singh S, Agarwal M, Gupta N (2017) Clinical impact of mismatch repair protein testing on outcome of early staged colorectal carcinomas. J Gastrointest Cancer 49:406\u2013414. https:\/\/doi.org\/10.1007\/s12029-017-9954-5","journal-title":"J Gastrointest Cancer"},{"issue":"5104","key":"717_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.8465203","volume":"260","author":"S Shirasawa","year":"1993","unstructured":"Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260(5104):85\u201388","journal-title":"Science"},{"issue":"6","key":"717_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","volume":"7","author":"Y Samuels","year":"2005","unstructured":"Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561\u2013573. https:\/\/doi.org\/10.1016\/j.ccr.2005.05.014","journal-title":"Cancer Cell"},{"issue":"6","key":"717_CR16","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1158\/0008-5472.CAN-07-5659","volume":"68","author":"M Jhawer","year":"2008","unstructured":"Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM (2008) PIK3CA mutation\/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953\u20131961. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5659","journal-title":"Cancer Res"},{"issue":"3","key":"717_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/73432","volume":"24","author":"DT Ross","year":"2000","unstructured":"Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24(3):227\u2013235. https:\/\/doi.org\/10.1038\/73432","journal-title":"Nat Genet"},{"issue":"1","key":"717_CR18","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41598-017-01964-1","volume":"7","author":"L Samaraweera","year":"2017","unstructured":"Samaraweera L, Adomako A, Rodriguez-Gabin A, McDaid HM (2017) A novel indication for panobinostat as a senolytic drug in NSCLC and HNSCC. Sci Rep 7(1):1900. https:\/\/doi.org\/10.1038\/s41598-017-01964-1","journal-title":"Sci Rep"},{"issue":"2","key":"717_CR19","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440\u2013446. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947","journal-title":"Cancer Res"},{"issue":"5","key":"717_CR20","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1017\/S1751731114003280","volume":"9","author":"Y Qin","year":"2015","unstructured":"Qin Y, Qi N, Tang Y, He J, Li X, Gu F, Zou S (2015) Isolation and identification of a high molecular weight protein in sow milk. Animal 9(5):847\u2013854. https:\/\/doi.org\/10.1017\/S1751731114003280","journal-title":"Animal"},{"issue":"5A","key":"717_CR21","first-page":"2625","volume":"28","author":"JP Palma","year":"2008","unstructured":"Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, Zhu GD, Penning TD, Luo Y, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK (2008) The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 28(5A):2625\u20132635","journal-title":"Anticancer Res"},{"issue":"8","key":"717_CR22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1080\/15384101.2015.1010866","volume":"14","author":"S Brookes","year":"2015","unstructured":"Brookes S, Gagrica S, Sanij E, Rowe J, Gregory FJ, Hara E, Peters G (2015) Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence. Cell Cycle 14(8):1164\u20131173. https:\/\/doi.org\/10.1080\/15384101.2015.1010866","journal-title":"Cell Cycle"},{"issue":"1\u20132","key":"717_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0022-1759(00)00233-7","volume":"243","author":"I Vermes","year":"2000","unstructured":"Vermes I, Haanen C, Reutelingsperger C (2000) Flow cytometry of apoptotic cell death. J Immunol Methods 243(1\u20132):167\u2013190","journal-title":"J Immunol Methods"},{"issue":"2","key":"717_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/ijo.2010.858","volume":"38","author":"BC He","year":"2011","unstructured":"He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He TC, Zhang BQ (2011) Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt\/ss-catenin signaling. Int J Oncol 38(2):437\u2013445. https:\/\/doi.org\/10.3892\/ijo.2010.858","journal-title":"Int J Oncol"},{"issue":"30","key":"717_CR25","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1016\/j.biomaterials.2009.07.015","volume":"30","author":"K Xiao","year":"2009","unstructured":"Xiao K, Luo J, Fowler WL, Li Y, Lee JS, Xing L, Cheng RH, Wang L, Lam KS (2009) A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30(30):6006\u20136016. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.07.015","journal-title":"Biomaterials"},{"issue":"3","key":"717_CR26","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.29244","volume":"66","author":"E Zhao","year":"2017","unstructured":"Zhao E, Ilyas G, Cingolani F, Choi JH, Ravenelle F, Tanaka KE, Czaja MJ (2017) Pentamidine blocks hepatotoxic injury in mice. Hepatology 66(3):922\u2013935. https:\/\/doi.org\/10.1002\/hep.29244","journal-title":"Hepatology"},{"issue":"1","key":"717_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1758834015614530","volume":"8","author":"WA Hammond","year":"2016","unstructured":"Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8(1):57\u201384. https:\/\/doi.org\/10.1177\/1758834015614530","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"717_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058089","volume":"8","author":"EL Bradshaw-Pierce","year":"2013","unstructured":"Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD (2013) Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 8(3):e58089. https:\/\/doi.org\/10.1371\/journal.pone.0058089","journal-title":"PLoS One"},{"issue":"5","key":"717_CR29","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.3892\/or.2015.3876","volume":"33","author":"H Tsukihara","year":"2015","unstructured":"Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, Uchida J, Matsuo K, Takechi T (2015) Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep 33(5):2135\u20132142. https:\/\/doi.org\/10.3892\/or.2015.3876","journal-title":"Oncol Rep"},{"issue":"4","key":"717_CR30","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/CCO.0000000000000091","volume":"26","author":"B Vormoor","year":"2014","unstructured":"Vormoor B, Curtin NJ (2014) Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol 26(4):428\u2013433. https:\/\/doi.org\/10.1097\/CCO.0000000000000091","journal-title":"Curr Opin Oncol"},{"issue":"21","key":"717_CR31","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588\u20135599. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753","journal-title":"Cancer Res"},{"issue":"2","key":"717_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/cr040478b","volume":"106","author":"DM Noll","year":"2006","unstructured":"Noll DM, Mason TM, Miller PS (2006) Formation and repair of interstrand cross-links in DNA. Chem Rev 106(2):277\u2013301. https:\/\/doi.org\/10.1021\/cr040478b","journal-title":"Chem Rev"},{"issue":"1","key":"717_CR33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.canlet.2016.02.007","volume":"374","author":"NH Nicolay","year":"2016","unstructured":"Nicolay NH, Ruhle A, Perez RL, Trinh T, Sisombath S, Weber KJ, Schmezer P, Ho AD, Debus J, Saffrich R, Huber PE (2016) Mesenchymal stem cells exhibit resistance to topoisomerase inhibition. Cancer Lett 374(1):75\u201384. https:\/\/doi.org\/10.1016\/j.canlet.2016.02.007","journal-title":"Cancer Lett"},{"issue":"2","key":"717_CR34","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/nar\/gku1307","volume":"43","author":"I Abdou","year":"2015","unstructured":"Abdou I, Poirier GG, Hendzel MJ, Weinfeld M (2015) DNA ligase III acts as a DNA strand break sensor in the cellular orchestration of DNA strand break repair. Nucleic Acids Res 43(2):875\u2013892. https:\/\/doi.org\/10.1093\/nar\/gku1307","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"717_CR35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","volume":"9","author":"E Stewart","year":"2014","unstructured":"Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, Karlstrom A, Calabrese C, Gordon B, Tsurkan L, Hatfield MJ, Potter PM, Snyder SE, Thiagarajan S, Shirinifard A, Sablauer A, Shelat AA, Dyer MA (2014) Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep 9(3):829\u2013841. https:\/\/doi.org\/10.1016\/j.celrep.2014.09.028","journal-title":"Cell Rep"},{"issue":"4","key":"717_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12275-016-6029-4","volume":"54","author":"TP Cao","year":"2016","unstructured":"Cao TP, Kim JS, Woo MH, Choi JM, Jun Y, Lee KH, Lee SH (2016) Structural insight for substrate tolerance to 2-deoxyribose-5-phosphate aldolase from the pathogen Streptococcus suis. J Microbiol 54(4):311\u2013321. https:\/\/doi.org\/10.1007\/s12275-016-6029-4","journal-title":"J Microbiol"},{"issue":"11","key":"717_CR37","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1128\/MCB.20.11.3977-3987.2000","volume":"20","author":"D Strumberg","year":"2000","unstructured":"Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y (2000) Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5\u2032-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 20(11):3977\u20133987","journal-title":"Mol Cell Biol"},{"issue":"7","key":"717_CR38","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1074\/jbc.C300437200","volume":"279","author":"M Malanga","year":"2004","unstructured":"Malanga M, Althaus FR (2004) Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J Biol Chem 279(7):5244\u20135248. https:\/\/doi.org\/10.1074\/jbc.C300437200","journal-title":"J Biol Chem"},{"issue":"7","key":"717_CR39","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1083\/jcb.200806068","volume":"183","author":"K Sugimura","year":"2008","unstructured":"Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K (2008) PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 183(7):1203\u20131212. https:\/\/doi.org\/10.1083\/jcb.200806068","journal-title":"J Cell Biol"},{"key":"717_CR40","doi-asserted-by":"publisher","unstructured":"Marechal A, Zou L (2013) DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol 5(9). https:\/\/doi.org\/10.1101\/cshperspect.a012716","DOI":"10.1101\/cshperspect.a012716"},{"issue":"3\u20134","key":"717_CR41","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000381029","volume":"95","author":"Y Kaku","year":"2015","unstructured":"Kaku Y, Tsuchiya A, Kanno T, Nishizaki T (2015) Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines. Pharmacology 95(3\u20134):154\u2013159. https:\/\/doi.org\/10.1159\/000381029","journal-title":"Pharmacology"},{"key":"717_CR42","doi-asserted-by":"publisher","unstructured":"Williams AB, Schumacher B (2016) p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 6(5). https:\/\/doi.org\/10.1101\/cshperspect.a026070","DOI":"10.1101\/cshperspect.a026070"},{"issue":"5","key":"717_CR43","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/onc.2012.84","volume":"32","author":"S Origanti","year":"2013","unstructured":"Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H (2013) Synthetic lethality of Chk1 inhibition combined with p53 and\/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32(5):577\u2013588. https:\/\/doi.org\/10.1038\/onc.2012.84","journal-title":"Oncogene"},{"issue":"1","key":"717_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellsig.2011.07.019","volume":"24","author":"ZY Abd Elmageed","year":"2012","unstructured":"Abd Elmageed ZY, Naura AS, Errami Y, Zerfaoui M (2012) The poly(ADP-ribose) polymerases (PARPs): new roles in intracellular transport. Cell Signal 24(1):1\u20138. https:\/\/doi.org\/10.1016\/j.cellsig.2011.07.019","journal-title":"Cell Signal"},{"issue":"2","key":"717_CR45","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10637-012-9886-7","volume":"31","author":"D Davidson","year":"2013","unstructured":"Davidson D, Wang Y, Aloyz R, Panasci L (2013) The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines. Investig New Drugs 31(2):461\u2013468. https:\/\/doi.org\/10.1007\/s10637-012-9886-7","journal-title":"Investig New Drugs"},{"issue":"4","key":"717_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1667\/RR003CC.1","volume":"187","author":"HB Lieberman","year":"2017","unstructured":"Lieberman HB, Panigrahi SK, Hopkins KM, Wang L, Broustas CG (2017) p53 and RAD9, the DNA damage response, and regulation of transcription networks. Radiat Res 187(4):424\u2013432. https:\/\/doi.org\/10.1667\/RR003CC.1","journal-title":"Radiat Res"},{"issue":"4","key":"717_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imm.12099","volume":"139","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Bennici E, Novelli F, Pioli C (2013) Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology 139(4):428\u2013437. https:\/\/doi.org\/10.1111\/imm.12099","journal-title":"Immunology"},{"issue":"7","key":"717_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132579","volume":"10","author":"YC Lee","year":"2015","unstructured":"Lee YC, Lee CH, Tsai HP, An HW, Lee CM, Wu JC, Chen CS, Huang SH, Hwang J, Cheng KT, Leiw PL, Chen CL, Lin CM (2015) Targeting of topoisomerase I for prognoses and therapeutics of camptothecin-resistant ovarian cancer. PLoS One 10(7):e0132579. https:\/\/doi.org\/10.1371\/journal.pone.0132579","journal-title":"PLoS One"},{"issue":"22","key":"717_CR49","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.1074\/jbc.M115.711051","volume":"291","author":"K Huang","year":"2016","unstructured":"Huang K, Zhang J, O'Neill KL, Gurumurthy CB, Quadros RM, Tu Y, Luo X (2016) Cleavage by caspase 8 and mitochondrial membrane association activate the BH3-only protein bid during TRAIL-induced apoptosis. J Biol Chem 291(22):11843\u201311851. https:\/\/doi.org\/10.1074\/jbc.M115.711051","journal-title":"J Biol Chem"},{"key":"717_CR50","doi-asserted-by":"publisher","unstructured":"McIlwain DR, Berger T, Mak TW (2015) Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol 7(4). https:\/\/doi.org\/10.1101\/cshperspect.a026716","DOI":"10.1101\/cshperspect.a026716"},{"issue":"5","key":"717_CR51","doi-asserted-by":"publisher","first-page":"705","DOI":"10.4149\/neo_2016_507","volume":"63","author":"D Mao","year":"2016","unstructured":"Mao D, Qiao L, Lu H, Feng Y (2016) B-cell translocation gene 3 overexpression inhibits proliferation and invasion of colorectal cancer SW480 cells via Wnt\/beta-catenin signaling pathway. Neoplasma 63(5):705\u2013716. https:\/\/doi.org\/10.4149\/neo_2016_507","journal-title":"Neoplasma"},{"issue":"3","key":"717_CR52","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/jclinpath-2015-202985","volume":"69","author":"N Melling","year":"2016","unstructured":"Melling N, Kowitz CM, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki JR, Marx AH (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 69(3):209\u2013214. https:\/\/doi.org\/10.1136\/jclinpath-2015-202985","journal-title":"J Clin Pathol"},{"issue":"30","key":"717_CR53","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.1523\/JNEUROSCI.0931-17.2017","volume":"37","author":"H Al-Ali","year":"2017","unstructured":"Al-Ali H, Ding Y, Slepak T, Wu W, Sun Y, Martinez Y, Xu XM, Lemmon VP, Bixby JL (2017) The mTOR substrate S6 kinase 1 (S6K1) is a negative regulator of axon regeneration and a potential drug target for central nervous system injury. J Neurosci 37(30):7079\u20137095. https:\/\/doi.org\/10.1523\/JNEUROSCI.0931-17.2017","journal-title":"J Neurosci"},{"issue":"7","key":"717_CR54","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3109\/0284186X.2014.895036","volume":"53","author":"C Therkildsen","year":"2014","unstructured":"Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M (2014) The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 53(7):852\u2013864. https:\/\/doi.org\/10.3109\/0284186X.2014.895036","journal-title":"Acta Oncol"},{"issue":"4","key":"717_CR55","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1078-0432.CCR-14-0894","volume":"21","author":"A Satelli","year":"2015","unstructured":"Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S (2015) Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res 21(4):899\u2013906. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0894","journal-title":"Clin Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-00717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-00717-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-00717-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:36:41Z","timestamp":1678559801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-00717-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,5]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["717"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-00717-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,5]]},"assertion":[{"value":"9 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Titto Augustine declares that he has no conflict of interest. Radhashree Maitra declares that she has no conflict of interest. Jinghang Zhang declares that she has no conflict of interest. Jay Nayak declares that he has no conflict of interest. Sanjay Goel declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants. All applicable institutional guidelines (by Institutional Animal Care and Use Committee) for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}